close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Claims Submission

The guidelines for submitting claims will vary based on the setting of care in which SYNVISC® is given. Physicians who administer SYNVISC in an office setting will bill Medicare and most other payers using the Blank CMS 1500 Claim Form (PDF, 87K). Hospitals that administer SYNVISC in the hospital outpatient setting will bill Medicare using the Blank CMS-1450 or UB-92 Claim Form (PDF, 17K).

For billing instructions:
Download the Sample CMS 1500 Claim Form (PDF, 225K) and the Sample CMS-1450 or UB-92 Claim Form (PDF, 15K).

It is important to verify your patients' unique coverage and access requirements before administering SYNVISC. For example, some payers may request additional information to confirm that SYNVISC therapy is appropriate for the patient's medical condition. This is referred to as prior authorization.

For assistance with insurance verifications, understanding prior authorization requirements, and claims support, you may contact SYNVISC ConnectionSM at 1-800-982-8292, M-F, 9am-6pm (EST).

Claims Resubmission and Appeals
In some cases, claims may be denied or pended for additional information. Often, this is due to coding errors. In some instances, however, claims are denied as the result of inadequate prior authorization, including:

  • Medical necessity was not justified.
    Download our Sample Medical Necessity Letter (Word, 31K) to provide written confirmation of the patient's condition.
  • Patient-specific benefits were limited or had been exhausted.
  • Prior authorization was required, but not obtained.
  • Required referrals were not received.

To file an appeal, use our Sample Appeal Letter (Word, 42K).

SYNVISC Connection can help you confirm prior authorization requirements, review your claims for proper coding, and resubmit or appeal denials when necessary.
Call 1-800-982-8292, M-F, 9am-6pm (EST).

Providers retain responsibility for determining reimbursement and insurance issues related to their patients. Genzyme cannot be responsible for failure of a provider to obtain reimbursement.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)